A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer

H Jo,M-S Lee,Y-P Lee,H Kim,J Y Hong, J Lee, S H Park,J O Park,Y S Park,H Y Lim,W K Kang,S T Kim

Clinical Oncology（2022）

引用 2|浏览24

暂无评分

摘要

•To compare the efficacy and safety of FOLFIRI plus bevacizumab or aflibercept in mCRC.•FOLFIRI–bevacizumab and FOLFIRI–aflibercept showed similar clinical efficacy.•The toxicity profiles were also largely similar between the two groups.•Both aflibercept and bevacizumab are suitable anti-angiogenic agents when used with FOLFIRI.

查看译文

关键词

Aflibercept,bevacizumab,colorectal cancer,target therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要